Abstract
The bone is the third most common site of cancer metastasis. To invade the bone, tumor cells produce osteoclast-activating factors that increase bone resorption by osteoclasts. Here we report that human neuroblastoma cells that form osteolytic lesions in vivo do not produce osteoclast-activating factors but rather stimulate osteoclast activity in the presence of human bone marrow mesenchymal stem cells. This alternative pathway of osteoclast activation involves a nonadhesive interaction between neuroblastoma cells and bone marrow mesenchymal stem cells. Stimulated bone marrow mesenchymal stem cells express markedly increased levels of interleukin-6, which is then responsible for osteoclast activation. This report describes a critical role of bone marrow mesenchymal stem cells in bone destruction in cancer.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1129-1135 |
| Number of pages | 7 |
| Journal | Cancer Research |
| Volume | 65 |
| Issue number | 4 |
| DOIs | |
| State | Published - Feb 15 2005 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Bone marrow mesenchymal stem cells provide an alternate pathway of osteoclast activation and bone destruction by cancer cells. / Sohara, Yasuyoshi; Shimada, Hiroyuki; Minkin, Cedric; Erdreich-Epstein, Anat; Nolta, Jan; DeClerck, Yves A.
In: Cancer Research, Vol. 65, No. 4, 15.02.2005, p. 1129-1135.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Bone marrow mesenchymal stem cells provide an alternate pathway of osteoclast activation and bone destruction by cancer cells
AU - Sohara, Yasuyoshi
AU - Shimada, Hiroyuki
AU - Minkin, Cedric
AU - Erdreich-Epstein, Anat
AU - Nolta, Jan
AU - DeClerck, Yves A.
PY - 2005/2/15
Y1 - 2005/2/15
N2 - The bone is the third most common site of cancer metastasis. To invade the bone, tumor cells produce osteoclast-activating factors that increase bone resorption by osteoclasts. Here we report that human neuroblastoma cells that form osteolytic lesions in vivo do not produce osteoclast-activating factors but rather stimulate osteoclast activity in the presence of human bone marrow mesenchymal stem cells. This alternative pathway of osteoclast activation involves a nonadhesive interaction between neuroblastoma cells and bone marrow mesenchymal stem cells. Stimulated bone marrow mesenchymal stem cells express markedly increased levels of interleukin-6, which is then responsible for osteoclast activation. This report describes a critical role of bone marrow mesenchymal stem cells in bone destruction in cancer.
AB - The bone is the third most common site of cancer metastasis. To invade the bone, tumor cells produce osteoclast-activating factors that increase bone resorption by osteoclasts. Here we report that human neuroblastoma cells that form osteolytic lesions in vivo do not produce osteoclast-activating factors but rather stimulate osteoclast activity in the presence of human bone marrow mesenchymal stem cells. This alternative pathway of osteoclast activation involves a nonadhesive interaction between neuroblastoma cells and bone marrow mesenchymal stem cells. Stimulated bone marrow mesenchymal stem cells express markedly increased levels of interleukin-6, which is then responsible for osteoclast activation. This report describes a critical role of bone marrow mesenchymal stem cells in bone destruction in cancer.
UR - http://www.scopus.com/inward/record.url?scp=13944258987&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=13944258987&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-04-2853
DO - 10.1158/0008-5472.CAN-04-2853
M3 - Article
C2 - 15734993
AN - SCOPUS:13944258987
VL - 65
SP - 1129
EP - 1135
JO - Journal of Cancer Research
JF - Journal of Cancer Research
SN - 0099-7013
IS - 4
ER -